|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.20 USD | +0.15% |
|
+6.34% | +22.44% |
| 06-09 | CVS Will Pay $36.5 Million to Settle Insulin Fraud Claims With State AGs, DOJ | DJ |
| 06-08 | UBS Adjusts Price Target on CVS Health to $115 From $100, Maintains Buy Rating | MT |
Company Valuation: CVS Health Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 136,274 | 122,449 | 101,613 | 56,490 | 100,742 | 123,842 | - | - |
| Change | - | -10.15% | -17.02% | -44.41% | 78.34% | 22.93% | - | - |
| Enterprise Value (EV) 1 | 179,925 | 160,658 | 151,768 | 111,767 | 154,714 | 179,720 | 176,152 | 174,323 |
| Change | - | -10.71% | -5.53% | -26.36% | 38.43% | 16.16% | -1.99% | -1.04% |
| P/E ratio | 17.3x | 29.7x | 12.2x | 12.3x | 57.1x | 15.6x | 13.5x | 11.7x |
| PBR | 1.81x | 1.71x | 1.33x | 0.75x | 1.34x | 1.55x | 1.46x | 1.36x |
| PEG | - | -0.6x | 0x | -0.3x | -0.9x | 0x | 0.9x | 0.8x |
| Capitalization / Revenue | 0.47x | 0.38x | 0.28x | 0.15x | 0.25x | 0.3x | 0.29x | 0.28x |
| EV / Revenue | 0.62x | 0.5x | 0.42x | 0.3x | 0.38x | 0.44x | 0.41x | 0.39x |
| EV / EBITDA | 9.2x | 8.04x | 7.59x | 7.68x | 9.06x | 9.5x | 8.59x | 7.66x |
| EV / EBIT | 10.4x | 9.16x | 8.66x | 9.33x | 10.7x | 11.4x | 10.2x | 9.06x |
| EV / FCF | 11.4x | 11.9x | 14.6x | 17.7x | 19.8x | 22.5x | 16.6x | 14x |
| FCF Yield | 8.75% | 8.37% | 6.85% | 5.66% | 5.05% | 4.44% | 6.04% | 7.16% |
| Dividend per Share 2 | 2 | 2.2 | 2.42 | 2.66 | - | 2.64 | 2.746 | 2.941 |
| Rate of return | 1.94% | 2.36% | 3.06% | 5.93% | - | 2.72% | 2.83% | 3.03% |
| EPS 2 | 5.95 | 3.14 | 6.47 | 3.66 | 1.39 | 6.213 | 7.198 | 8.282 |
| Distribution rate | 33.6% | 70.1% | 37.4% | 72.7% | - | 42.5% | 38.2% | 35.5% |
| Net sales 1 | 292,111 | 322,467 | 357,776 | 372,809 | 402,067 | 409,232 | 425,817 | 447,396 |
| EBITDA 1 | 19,565 | 19,971 | 19,995 | 14,548 | 17,073 | 18,918 | 20,506 | 22,764 |
| EBIT 1 | 17,312 | 17,532 | 17,534 | 11,976 | 14,443 | 15,739 | 17,352 | 19,251 |
| Net income 1 | 7,910 | 4,149 | 8,344 | 4,614 | 1,768 | 7,968 | 9,300 | 10,470 |
| Net Debt 1 | 43,651 | 38,209 | 50,155 | 55,277 | 53,972 | 55,879 | 52,311 | 50,482 |
| Reference price 2 | 103.16 | 93.19 | 78.96 | 44.89 | 79.36 | 97.06 | 97.06 | 97.06 |
| Nbr of stocks (in thousands) | 1,321,000 | 1,313,967 | 1,286,897 | 1,258,408 | 1,269,432 | 1,275,927 | - | - |
| Announcement Date | 09/02/22 | 08/02/23 | 07/02/24 | 12/02/25 | 10/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 15.62x | 0.44x | 9.5x | 2.72% | 124B | ||
| 12.41x | 1.65x | 8.14x | 0.83% | 83.17B | ||
| 11.11x | 1.32x | 8.01x | 3.06% | 24.2B | ||
| 21.23x | 2.33x | 11.75x | 1.57% | 22.64B | ||
| 29.21x | 5.31x | 22.28x | 2.42% | 20.07B | ||
| 6.6x | 1.12x | 5.3x | -.--% | 14.33B | ||
| 14.85x | 1.4x | 7.15x | 4.73% | 14.14B | ||
| 13.52x | 1.67x | 8.02x | 0.84% | 12.72B | ||
| 12.67x | 0.99x | 5.52x | 3.59% | 11.99B | ||
| 58.96x | 9.99x | 38.66x | 0.17% | 10.24B | ||
| Average | 19.62x | 2.62x | 12.43x | 1.99% | 33.73B | |
| Weighted average by Cap. | 16.41x | 1.64x | 10.38x | 2.03% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CVS Stock
- Valuation CVS Health Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















